Group 1 - Frontier Biotechnologies has entered into a deal with GSK, granting GSK worldwide rights to develop two small interfering RNA therapies targeting kidney diseases [1] - The agreement could be worth up to $1 billion, indicating significant potential for both companies in the biopharmaceutical market [1] - This collaboration highlights the growing interest and investment in RNA-based therapies within the healthcare and pharmaceutical industry [1]